Patents Examined by Jason Sims
-
Patent number: 9877961Abstract: Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds.Type: GrantFiled: November 10, 2016Date of Patent: January 30, 2018Assignee: PEROSPHERE INC.Inventors: Solomon S. Steiner, Bryan E. Laulicht, Sasha H. Bakhru, Edith Mathiowitz
-
Patent number: 9875336Abstract: A computer system aligns two or more sequences with each other to identify similarities and differences between the aligned sequences. The sequences may, for example, represent proteins. The system performs alignment quickly and accurately by representing the sequences as perceptual information and conceptual information having mappings between them in a knowledgebase, and then performing the alignment based on the representations of the sequences in the knowledgebase. The alignment may be performed in polynomial time, regardless of the number of sequences that are aligned.Type: GrantFiled: September 15, 2015Date of Patent: January 23, 2018Inventors: Sherwin Han, Aihua Pan
-
Patent number: 9846762Abstract: Described are mathematical models and method, e.g., computer-implemented methods, for predicting tumor sensitivity to radiation therapy, which can be used, e.g., for selecting a treatment for a subject who has a tumor.Type: GrantFiled: August 28, 2013Date of Patent: December 19, 2017Assignee: University of South FloridaInventors: Javier F. Torres-Roca, Steven Eschrich
-
Patent number: 9827229Abstract: The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.Type: GrantFiled: October 3, 2014Date of Patent: November 28, 2017Assignee: INVENIO THERAPEUTICS INC.Inventors: Mahesh K. Gundluru, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, David Wald
-
Patent number: 9829311Abstract: A force measurement system that includes at least one force plate module is disclosed herein. The at least one force plate module has a plurality of force plate assemblies supported on a base component, each of the force plate assemblies includes a plate component having a top surface, the top surface of the plate component forming a force measurement surface for receiving at least one portion of a body of a subject; and at least one force transducer, the at least one force transducer configured to sense one or more measured quantities and output one or more signals that are representative of the one or more measured quantities, the plate component being supported on the at least one force transducer. The at least one force plate module is configured to be connected to one or more additional force plate modules so as to form a modular array of force plates.Type: GrantFiled: November 30, 2015Date of Patent: November 28, 2017Assignee: Bertec CorporationInventors: Todd Christopher Wilson, Necip Berme, Jan Jakub Ober
-
Patent number: 9792403Abstract: Methods and systems for analyzing genetic variants are disclosed.Type: GrantFiled: May 9, 2014Date of Patent: October 17, 2017Assignee: FOUNDATION MEDICINE, INC.Inventors: James Xin Sun, Roman Yelensky
-
Patent number: 9784678Abstract: There is provided an improved method for enhancing fluorescence images of an object, such as a biological tissue, by selectively eliminating or reducing unwanted fluorescence from fluorophores other than the fluorophore of interest. The method is based on the measurement of the lifetime of fluorophores while preserving information related to the fluorescence intensity of the fluorophore of interest.Type: GrantFiled: December 23, 2005Date of Patent: October 10, 2017Assignee: SOFTSCAN HEALTHCARE GROUP LTD.Inventor: Guobin Ma
-
Patent number: 9777328Abstract: The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.Type: GrantFiled: January 19, 2010Date of Patent: October 3, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Stephen Quake, Hei-Mun Christina Fan
-
Patent number: 9771345Abstract: The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 ?M and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.Type: GrantFiled: October 7, 2010Date of Patent: September 26, 2017Assignees: Cornell University, Purdue Research Foundation, BlinkBio, Inc.Inventors: Francis Barany, Maneesh Pingle, Sarah Filippa Giardina, Donald Bergstrom, Lee Daniel Arnold
-
Patent number: 9763444Abstract: Chromene derivatives based on a chromene amide isolated from Amyris texana. Also disclosed are compositions containing chromene derivatives (synthetic or natural) based on a chromene amide isolated from Amyris texana. Also methods for repelling blood-sucking and biting insects, ticks and mites involving treating (or exposing) an object (e.g., mammals such as humans) or area (e.g., a surface such as human skin) with a blood-sucking and biting insects, ticks and mites repelling effective amount of at least one compound selected from chromene derivatives (synthetic or natural) based on a chromene amide isolated from Amyris texana.Type: GrantFiled: February 23, 2016Date of Patent: September 19, 2017Assignee: The United States of America, as Represented by the Secretary of AgricultureInventors: Kumudini M. Meepagala, Ulrich R. Bernier
-
Patent number: 9757359Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.Type: GrantFiled: May 2, 2013Date of Patent: September 12, 2017Assignees: REATA PHARMACEUTICALS, INC., TRUSTEES OF DARTMOUTH COLLEGEInventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
-
Patent number: 9752096Abstract: The present invention relates to the field of perfumery and provides certain bi-cyclo derivatives of formula (I) wherein R1 represents a hydrogen atom or a C1-2 alkyl group; R2 represents a hydrogen atom or a methyl group; and A represents a group of formula C3-5 alkanediyl group; at least one of said R1 or R2 represents a group containing at least one carbon atom. The compounds are in the form of a E or Z isomer or of a mixture thereof. These compounds are valuable perfuming ingredients capable of imparting lily of the valley and citrus notes to consumer products.Type: GrantFiled: June 30, 2014Date of Patent: September 5, 2017Assignee: Firmenich SAInventor: Robert Moretti
-
Patent number: 9750731Abstract: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.Type: GrantFiled: August 21, 2014Date of Patent: September 5, 2017Assignee: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Lin Chen, Nimanthi Jayathilaka, Aidong Han, Nicos Petasis
-
Patent number: 9746461Abstract: A urine analyzer capable of operating in a urine measurement mode and a body fluid measurement mode, the urine analyzer includes a specimen preparing section configured to prepare a measurement specimen and a detecting section configured to derive signals of particles in the measurement specimen supplied from the specimen preparing section. A computer and a memory including programs on a computer-readable medium that enable the computer to execute operations to control the specimen preparing section and the detecting section in the urine measurement mode and in the body fluid measurement mode.Type: GrantFiled: February 28, 2014Date of Patent: August 29, 2017Assignee: SYSMEX CORPORATIONInventors: Masakazu Fukuda, Masamichi Tanaka
-
Patent number: 9744163Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: March 13, 2014Date of Patent: August 29, 2017Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger, Joseph Niemann
-
Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
Patent number: 9738629Abstract: Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus C(HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.Type: GrantFiled: January 22, 2015Date of Patent: August 22, 2017Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Hongming Xie, Jiancun Zhang, Bailin Hu, Qinghong Fang, Qingyun Ren -
Patent number: 9738639Abstract: The present invention provides pyrroloquinoline quinone lithium salt crystal and a preparation method and application thereof. Characteristic absorption peaks appear when the diffraction angles are 6.222±0.2°, 7.379±0.2°, 7.941±0.2°, 23.631±0.2°, 24.044±0.2°, 25.497±0.2°, 27.541±0.2°, 30.736±0.2°, and 32.306±0.2° degrees in a powder X-ray diffraction pattern of the pyrroloquinoline quinine lithium salt crystal. The maximum value of thermal absorption of the pyrroloquinoline quinine lithium salt crystal appears between 90° C. and 96° C. through differential scanning calorimetry. Peaks appear when infrared spectroscopy of the pyrroloquinoline quinine lithium salt crystal is at 3396.03 cm?1, 1652.70 cm?1, 1604.48 cm?1, 1500.35 cm?1, 1355.71 cm?1, 1243.86 cm?1, 1147.44 cm?1, 808.03 cm?1, 761.74 cm?1, and 570.83 cm?1. The pyrroloquinoline quinine lithium salt polymorphism can be applied to preparation of medicines for curing memory damage.Type: GrantFiled: June 23, 2014Date of Patent: August 22, 2017Assignee: Shanghai Ri Xin Biotechnology Co., Ltd.Inventors: Chunjiu Zhong, Xuefeng Mei, Huan Zhang
-
Patent number: 9732087Abstract: Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.Type: GrantFiled: August 14, 2014Date of Patent: August 15, 2017Assignee: JANSSEN PHARMACEUTICA N.V.Inventors: Hui Cai, Frank Chavez, Paul J. Dunford, Andrew J. Greenspan, Steven P. Meduna, Jorge A. Quiroz, Brad M. Savall, Kevin L. Tays, Robin L. Thurmond, Jianmei Wei, Ronald L. Wolin, Xiaohu Zhang
-
Patent number: 9714451Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: GrantFiled: September 27, 2013Date of Patent: July 25, 2017Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: John D. Shaughnessy, Jr., Bart Barlogie, Fenghuang Zhan
-
Patent number: 9714454Abstract: The present invention relates to detection of materials derived from transgenic plant events. In particular, the invention provides methods, reagents, kits and reference materials for detecting the presence or absence in a sample of genetic material derived from and attributable to select transgenic plant events.Type: GrantFiled: February 7, 2014Date of Patent: July 25, 2017Assignee: Scientific Institute of Public HealthInventors: Marc Henri Germain Van Den Bulcke, Antoon Piet Nelly Raoul Lievens, Amaya Leunda, Etondoh Guillaume Mbongolo Mbella, Elodie Barbau-Piednoir, Myriam Jacqueline Sylviane Sneyers